“The future of autoimmunity is being reprogrammed in real time, and iPSC CAR‑T cells are helping to write the code.”Abi Pinchbeck, Commissioning Editor, Cell & Gene Therapy Insights, speaks with John (Bobby) Goulding, Director, Corporate Strategy, Fate Therapeutics, who takes an in‑depth look at induced pluripotent stem cell (iPSC)-derived allogeneic CAR‑T cells and their potential clinical application in autoimmune disease, including safety‑by‑design considerations, clinical trial considerations, manufacturing scalability, and democratizing outpatient access.
John Goulding (Tue,) studied this question.